Redmile Group is an SEC-registered investment adviser based in Larkspur, CA that reports managing 10 hedge funds on Form ADV. It reports $4.7 billion in regulatory assets under management. Its private funds, of all types, hold $4.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +20.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +66.1% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $4.7 billionForm ADV Item 5.F
- Gross assets of private funds
- $4.6 billionAll private fund types, Form ADV
- Hedge funds managed
- 1020 private funds in total
- Employees
- 30Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 143606
- Latest Form ADV
- 08/28/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +21.5% | +14.8% |
| Q1 2026 | -1.0% | -4.6% |
| Q4 2025 | +34.7% | +2.4% |
| Q3 2025 | +23.1% | +7.8% |
| Q2 2025 | +10.8% | +10.4% |
| Q1 2025 | -23.3% | -4.5% |
| Q4 2024 | -10.4% | +2.1% |
| Q3 2024 | +9.5% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 44 share positions ($1,366,251,642) reported by Redmile Group, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Nurix Therapeutics Inc13.71%
- Krystal Biotech Inc12.84%
- Scholar Rock Hldg Corp10.73%
- Stoke Therapeutics Inc7.36%
- Immunome Inc6.87%
- Absci Corporation5.26%
- Electra Therapeutics Inc4.47%
- Annexon Inc4.42%
- Neurogene Inc3.18%
- Regenxbio Inc2.78%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Nurix Therapeutics Inc | $187,334,725 | 13.71% | 7,901,085 | +93.95% |
| Krystal Biotech Inc | $175,486,591 | 12.84% | 527,684 | -16.51% |
| Scholar Rock Hldg Corp | $146,601,044 | 10.73% | 3,033,962 | -29.62% |
| Stoke Therapeutics Inc | $100,594,728 | 7.36% | 3,869,028 | -1.95% |
| Immunome Inc | $93,849,507 | 6.87% | 4,363,064 | -11.17% |
| Absci Corporation | $71,850,730 | 5.26% | 6,671,377 | -1.01% |
| Electra Therapeutics Inc | $61,097,828 | 4.47% | 5,430,918 | New |
| Annexon Inc | $60,396,257 | 4.42% | 14,278,075 | +20.29% |
| Neurogene Inc | $43,460,376 | 3.18% | 1,562,199 | +10.62% |
| Regenxbio Inc | $38,015,220 | 2.78% | 5,048,502 | +15.56% |
| Shattuck Labs Inc | $34,693,272 | 2.54% | 5,086,990 | -26.19% |
| Fate Therapeutics Inc | $30,508,882 | 2.23% | 12,872,946 | Unchanged |
| Silence Therapeutics PLC | $26,897,571 | 1.97% | 2,460,894 | +13.68% |
| Beam Therapeutics Inc | $25,960,570 | 1.90% | 1,061,782 | -8.80% |
| Attovia Therapeutics Inc | $19,943,881 | 1.46% | 1,163,587 | New |
| Agomab Therapeutics NV | $19,316,553 | 1.41% | 1,740,230 | -36.35% |
| Nuvation Bio Inc | $16,973,650 | 1.24% | 3,031,009 | Unchanged |
| Adarx Pharmaceuticals Inc | $15,340,739 | 1.12% | 769,345 | New |
| Ideaya Biosciences Inc | $14,650,276 | 1.07% | 381,319 | -40.44% |
| Adc Therapeutics SA | $14,133,153 | 1.03% | 11,584,552 | +0.50% |
| Solid Biosciences Inc | $14,057,593 | 1.03% | 1,944,342 | -0.22% |
| Zymeworks Inc | $13,023,914 | 0.95% | 491,654 | Unchanged |
| Obsidian Therapeutics Inc | $11,439,246 | 0.84% | 833,157 | New |
| Biomarin Pharmaceutical Inc | $11,372,280 | 0.83% | 189,538 | -28.52% |
| Climb Bio Inc | $11,177,389 | 0.82% | 974,489 | -20.54% |
| Celldex Therapeutics Inc New | $10,428,566 | 0.76% | 321,770 | -25.85% |
| Alx Oncology Hldgs Inc | $9,987,516 | 0.73% | 7,185,263 | -2.80% |
| Aura Biosciences Inc | $9,749,568 | 0.71% | 1,552,479 | -6.85% |
| Cogent Biosciences Inc | $9,497,324 | 0.70% | 296,606 | -41.07% |
| Ceribell Inc | $9,433,711 | 0.69% | 386,786 | Unchanged |
| Odyssey Therapeutics Inc | $8,321,612 | 0.61% | 374,510 | -11.88% |
| Xenon Pharmaceuticals Inc | $7,104,629 | 0.52% | 191,036 | -16.71% |
| Livanova PLC | $6,436,098 | 0.47% | 84,132 | -9.69% |
| Atara Biotherapeutics Inc | $5,413,242 | 0.40% | 636,852 | +44.18% |
| Insmed Inc | $4,896,834 | 0.36% | 42,902 | -16.26% |
| Eupraxia Pharmaceuticals Inc | $4,730,917 | 0.35% | 519,881 | -14.97% |
| DBV Technologies S A | $4,391,384 | 0.32% | 373,417 | -9.02% |
| Oric Pharmaceuticals Inc | $3,944,245 | 0.29% | 292,817 | -19.11% |
| Tcgx Acquisition Corp | $3,751,249 | 0.27% | 299,860 | New |
| Prime Medicine Inc | $3,503,657 | 0.26% | 1,146,860 | -17.47% |
| Invivyd Inc | $1,988,457 | 0.15% | 2,285,320 | -12.03% |
| Ocular Therapeutix Inc | $1,871,127 | 0.14% | 243,954 | New |
| Ardelyx Inc | $1,791,635 | 0.13% | 523,870 | -18.37% |
| Pliant Therapeutics Inc | $833,896 | 0.06% | 772,126 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 6 new positions, 1 sold out, 7 increased, 26 reduced and 5 unchanged.
Number of positions (a count, not dollars)
- New positions6
- Increased7
- Unchanged5
- Reduced26
- Sold out1
New positions
| Stock | Value | Shares |
|---|---|---|
| Electra Therapeutics Inc | $61,097,828 | 5,430,918 |
| Attovia Therapeutics Inc | $19,943,881 | 1,163,587 |
| Adarx Pharmaceuticals Inc | $15,340,739 | 769,345 |
| Obsidian Therapeutics Inc | $11,439,246 | 833,157 |
| Tcgx Acquisition Corp | $3,751,249 | 299,860 |
| Ocular Therapeutix Inc | $1,871,127 | 243,954 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Establishment Labs Hldgs Inc | $7,634,001 | 88,964 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Nurix Therapeutics Inc | +3,827,298 | +93.95% | $187,334,725 | 7,901,085 |
| Annexon Inc | +2,408,198 | +20.29% | $60,396,257 | 14,278,075 |
| Regenxbio Inc | +679,698 | +15.56% | $38,015,220 | 5,048,502 |
| Neurogene Inc | +150,000 | +10.62% | $43,460,376 | 1,562,199 |
| Silence Therapeutics PLC | +296,117 | +13.68% | $26,897,571 | 2,460,894 |
| Atara Biotherapeutics Inc | +195,151 | +44.18% | $5,413,242 | 636,852 |
| Adc Therapeutics SA | +57,842 | +0.50% | $14,133,153 | 11,584,552 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Scholar Rock Hldg Corp | -1,277,130 | -29.62% | $146,601,044 | 3,033,962 |
| Krystal Biotech Inc | -104,321 | -16.51% | $175,486,591 | 527,684 |
| Shattuck Labs Inc | -1,805,043 | -26.19% | $34,693,272 | 5,086,990 |
| Immunome Inc | -548,526 | -11.17% | $93,849,507 | 4,363,064 |
| Agomab Therapeutics NV | -993,696 | -36.35% | $19,316,553 | 1,740,230 |
| Ideaya Biosciences Inc | -258,883 | -40.44% | $14,650,276 | 381,319 |
| Cogent Biosciences Inc | -206,715 | -41.07% | $9,497,324 | 296,606 |
| Biomarin Pharmaceutical Inc | -75,631 | -28.52% | $11,372,280 | 189,538 |
| Celldex Therapeutics Inc New | -112,151 | -25.85% | $10,428,566 | 321,770 |
| Climb Bio Inc | -251,841 | -20.54% | $11,177,389 | 974,489 |
| Beam Therapeutics Inc | -102,477 | -8.80% | $25,960,570 | 1,061,782 |
| Stoke Therapeutics Inc | -76,892 | -1.95% | $100,594,728 | 3,869,028 |
| Xenon Pharmaceuticals Inc | -38,338 | -16.71% | $7,104,629 | 191,036 |
| Odyssey Therapeutics Inc | -50,490 | -11.88% | $8,321,612 | 374,510 |
| Insmed Inc | -8,332 | -16.26% | $4,896,834 | 42,902 |
| Oric Pharmaceuticals Inc | -69,193 | -19.11% | $3,944,245 | 292,817 |
| Eupraxia Pharmaceuticals Inc | -91,519 | -14.97% | $4,730,917 | 519,881 |
| Prime Medicine Inc | -242,772 | -17.47% | $3,503,657 | 1,146,860 |
| Absci Corporation | -68,298 | -1.01% | $71,850,730 | 6,671,377 |
| Aura Biosciences Inc | -114,188 | -6.85% | $9,749,568 | 1,552,479 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| AgomAb Therapeutics NV | 13G amendment | 3.5% | 1,740,230 | Nov 16, 2026 | SEC.gov ↗ |
| Fate Therapeutics Inc | 13D amendment | 14.99% | 19,164,572 | Nov 9, 2026 | SEC.gov ↗ |
| Electra Therapeutics, Inc. | 13G | 8.7% | 5,462,881 | Sep 28, 2026 | SEC.gov ↗ |
| Nurix Therapeutics, Inc. | 13G amendment | 8.1% | 8,782,256 | Aug 14, 2026 | SEC.gov ↗ |
| Neurogene Inc. | 13G amendment | 9.9% | 1,572,202 | Aug 14, 2026 | SEC.gov ↗ |
| Scholar Rock Holding Corporation | 13G amendment | 3.6% | 4,311,092 | Aug 14, 2026 | SEC.gov ↗ |
| Atara Biotherapeutics, Inc. | 13D amendment | 9.9% | 950,994 | Jul 24, 2026 | SEC.gov ↗ |
| Shattuck Labs, Inc. | 13D amendment | 9.9% | 10,019,421 | Jul 17, 2026 | SEC.gov ↗ |
| Annexon, Inc. | 13G amendment | 9.9% | 17,918,459 | Jul 8, 2026 | SEC.gov ↗ |
| Stoke Therapeutics, Inc. | 13G amendment | 6.7% | 4,164,120 | May 15, 2026 | SEC.gov ↗ |
| Immunome, Inc. | 13G amendment | 4.9% | 5,558,885 | May 15, 2026 | SEC.gov ↗ |
| ALX Oncology Holdings Inc. | 13G amendment | 6.8% | 9,214,188 | May 15, 2026 | SEC.gov ↗ |
| ADC Therapeutics SA | 13G amendment | 9.9% | 12,717,487 | Apr 24, 2026 | SEC.gov ↗ |
| Absci Corporation | 13D amendment | 4.9% | 7,607,449 | Apr 14, 2026 | SEC.gov ↗ |
| Zymeworks Inc. | 13G amendment | 4.9% | 3,705,750 | Nov 14, 2025 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 16 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (5)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (18)
As reported in the adviser's Form ADV filed Jul 3, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures